Inhibikase Therapeutics Reports Results from Phase 2 201 Trial for Risvodetinib
On January 29, 2025, Inhibikase Therapeutics, Inc. (NYSE:IKT) disclosed findings from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease. The 201 Trial involved 126 individuals with untreated Parkinson’s disease who were, on average, 14 months post-diagnosis. Participants received doses of 50 […]
More Stories
Trump Offers White House Press Secretary Job to UFC Chief Dana White
By Sylvia Xu President Donald Trump said on Saturday that he offered the White House press secretary job to Ultimate...
Cost of Living, AI Bubble Top Consumer Concerns in November: UMich
By Andrew Moran U.S. consumer sentiment rebounded this month, but concerns surrounding ongoing cost-of-living issues and a potential artificial intelligence...
Wendy’s Rejects $1.4 Billion Buyout Offer From Nelson Peltz-Led Group
By Bill Pan Wendy’s has rejected a $1.4 billion takeover offer from billionaire investor Nelson Peltz, saying the proposal “substantially...
Best Family Halloween Movies to Watch
Halloween movies for families is one of the most searched phrases before Halloween night every year. October is the perfect...
GOP Rep. Luna Wins Reelection to House District in Florida
By Zachary Stieber Rep. Anna Paulina Luna (R-Fla.) has won another term representing Florida in the U.S. House of Representatives....
National Veterans Parade Expected to Draw 50,000 to DC
By Timothy Frudd The National Veterans Parade is expected to draw 50,000 people to the streets of Washington on Sunday...